Balancing Accelerated Approval for Drugs With Accelerated Withdrawal--Reply

Affiliations

¹ Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
² Division of Hematology Oncology/Knight Cancer Institute, Oregon Health & Science University, Portland3Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland4Senior Scholar in the Center for Health Care Ethics, Or.

Comment

Chul Kim et al. JAMA Intern Med. 2016 Apr.

. 2016 Apr;176(4):567.

doi: 10.1001/jamainternmed.2016.0374.

¹ Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
² Division of Hematology Oncology/Knight Cancer Institute, Oregon Health & Science University, Portland3Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland4Senior Scholar in the Center for Health Care Ethics, Or.

No abstract available

Comment on

Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.
Kim C, Prasad V. Kim C, et al. JAMA Intern Med. 2015 Dec;175(12):1992-4. doi: 10.1001/jamainternmed.2015.5868. JAMA Intern Med. 2015. PMID: 26502403 No abstract available.
Balancing Accelerated Approval for Drugs With Accelerated Withdrawal.
Braillon A, Menkes DB. Braillon A, et al. JAMA Intern Med. 2016 Apr;176(4):566-7. doi: 10.1001/jamainternmed.2016.0351. JAMA Intern Med. 2016. PMID: 27043114 No abstract available.